BIIB — BIOGEN INC.

—
Nasdaq · Health Care · Biotechnology · CIK 875045 ·
Last close
$250.79
Market Cap
$37.07B
52W High
$261.00
52W Low
$160.36
ADV30
1,244,142
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 2,736,000,000 1,959,100,000 482,800,000 97,500,000 32,086,600,000 1,285,000,000 13,238,600,000
Mar 2026 2,477,800,000 1,816,800,000 459,800,000 319,500,000 29,483,100,000 3,382,700,000 10,831,400,000
Dec 2025 2,279,400,000 1,783,900,000 385,500,000 -48,900,000 29,439,500,000 3,008,500,000 11,182,700,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,878,800,000
Investing CF
$-5,315,500,000
Financing CF
$985,000,000
CapEx
$-388,800,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.34
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$20,969,700,000
Inventory
$2,384,300,000
Receivables
$2,398,400,000
ST Investments
$0
EBIT TTM
$1,296,200,000
Pretax Income TTM
$1,011,400,000
Interest Exp TTM
$284,800,000
Analysts
32

Yahoo Snapshot (yfinance, live)

Total Revenue
$10,297,299,968
EBITDA
$3,302,099,968
Free Cash Flow
$808,124,992
Enterprise Value
$43,987,566,592
Total Cash
$1,303,900,032
Total Debt
$7,801,299,968
Shares Out
147,820,223
Trailing EPS
$2.31
Book Value
$128.01
ROE
1.9%
ROA
4.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 9,890,600,000 2,469,000,000 1,292,900,000 29,439,500,000 11,182,700,000 18,256,800,000 2,204,600,000
Dec 2024 9,675,900,000 2,280,400,000 1,632,200,000 28,049,300,000 11,333,300,000 16,716,000,000 2,875,500,000
Dec 2023 9,835,600,000 1,847,700,000 1,161,100,000 26,844,800,000 12,045,400,000 14,799,400,000 1,547,200,000
Dec 2022 10,173,400,000 2,901,900,000 3,046,900,000 24,554,100,000 11,165,700,000 13,397,900,000 1,384,300,000

TTM Snapshot

Revenues TTM
$10,027,900,000
NetIncome TTM
$834,600,000
OpCashFlow TTM
—
Assets (Latest)
$32,086,600,000
Forward EPS
$16.27

Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $260.00 · spot: $251.41 · call volume: 125 · put volume: 1,081
Expected Move to 2027-06-17: ±$64.77 (25.76%) — implied range $186.64 – $316.18 · ATM straddle on $250.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RVMD Revolution Medicines, Inc. $35.19B $162.69 —
ARGX ARGENX SE $58.92B $947.52 —
BNTX BioNTech SE $21.32B $84.86 —
NBIX NEUROCRINE BIOSCIENCES INC $16.79B $165.92 —
EXEL EXELIXIS, INC. $16.71B $68.50 —

News headlines (Yahoo Finance, 1h cache)

Biogen reports two-year Phase II data for diranersen in Alzheimer’s
2026-11-19 09:59 · Yahoo
What Could Biogen (BIIB) Gain From Its New Protein Degrader Research Deal?
2026-11-19 03:29 · Yahoo
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
2026-11-18 16:00 · Yahoo
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
2026-11-18 15:16 · Yahoo
Biogen (BIIB) Stock May Be 49% Undervalued After Fresh Alzheimer’s Data
2026-11-18 14:14 · Yahoo
Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
2026-11-18 13:11 · Yahoo
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
2026-11-17 23:12 · Yahoo
Biogen: 3 Key Takeaways for Long-Term Investors
2026-11-17 22:05 · Yahoo
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
2026-11-17 21:45 · Yahoo
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
2026-11-16 23:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.